MARÍA BELÉN
LÓPEZ MILLÁN
CONTRATADA DE INVESTIGACIÓN POSTDOCTORAL
Instituto de Salud Carlos III
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (11)
2022
-
Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia
Molecular Oncology, Vol. 16, Núm. 16, pp. 2899-2919
-
Robust in Vitro and in Vivo Immunosuppressive and Anti-inflammatory Properties of Inducible Caspase-9-mediated Apoptotic Mesenchymal Stromal/Stem Cell
Stem Cells Translational Medicine, Vol. 11, Núm. 1, pp. 88-96
-
The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia
Cancers, Vol. 14, Núm. 6
2021
-
Engraftment characterization of risk-stratified AML in NSGS mice
Blood Advances, Vol. 5, Núm. 23, pp. 4842-4854
2020
-
Bone marrow clonogenic myeloid progenitors from NPM1-mutated AML patients do not harbor the NPM1 mutation: Implication for the cell-of-origin of NPM1+ AML
Genes, Vol. 11, Núm. 1
-
Robustness of Catalytically Dead Cas9 Activators in Human Pluripotent and Mesenchymal Stem Cells
Molecular Therapy - Nucleic Acids, Vol. 20, pp. 196-204
2018
-
Correction to: NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL (Leukemia, (2018), 32, 3, (633-644), 10.1038/leu.2017.294)
Leukemia
-
IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC/Idarubicin activity in preclinical models of non del5q/5q- AML
OncoImmunology, Vol. 7, Núm. 9
-
NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL
Leukemia, Vol. 32, Núm. 3, pp. 633-644
2017
-
Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes
Stem Cell Reports, Vol. 8, Núm. 6, pp. 1573-1586